Hikma and M42 sign strategic MoU to advance healthcare innovation in the UAE
The MOU was signed on the sidelines of the Arab Health 2025 conference and aims to accelerate the implementation of more precise, preventive and predictive cancer care programmes, utilising cutting-edge genomics screening technology. Under this agreement, Hikma and M42 will enhance their collaboration to promote the use of Shield™, a non-invasive laboratory-developed test (LDT) by Guardant Health Inc., for colorectal cancer (CRC) screening, aiming to improve screening adherence rates in the UAE. Shield™ is the first blood test to be approved by the US FDA as a primary screening option for CRC, meaning healthcare providers can offer Shield in a manner similar to all other non-invasive methods recommended in screening guidelines.
The Abu Dhabi Public Health Centre (ADPHC), in partnership with M42, recently introduced the non-invasive blood-based liquid biopsy test Shield™ for colorectal cancer screening as part of the IFHAS comprehensive health screening programme. Shield™ is already available for screening at key healthcare centres and M42 locations across Abu Dhabi, Al Ain and the Al Dhafra region.
Mazen Darwazah, Hikma's Executive Vice Chairman and President of MENA, said: ' We are proud to sign this strategic partnership with M42 – a company that shares our commitment to innovation shaping the future of healthcare to improve patient outcomes. This important endeavour is focused on enhancing early disease detection, enabling more precise diagnoses, and facilitating more effective treatments, particularly in oncology and preventive care, which is aligned with our ambition of providing broader healthcare solutions focused on precision medicine.'
Dr. Fahed Al Marzooqi, Chief Executive Officer, Integrated Health Solutions, M42, said: 'At M42, we are committed to harnessing cutting-edge technologies to improve patient outcomes and empower health systems to deliver proactive care. This collaboration with Hikma reflects our dedication to supporting Abu Dhabi's broader efforts to lead in next-generation screening and health innovation. By integrating AI and genomics-driven solutions, we are redefining traditional healthcare models to create a healthier, more sustainable future for all.'
Last year Hikma announced that it had signed an exclusive agreement with Guardant Health, Inc. for the commercialisation and marketing of Guardant Health's portfolio of liquid and tissue biopsy tests for cancer screening, recurrence monitoring and tumour mutation profiling across all solid cancers in the Middle East and North Africa (MENA). The agreement includes tests such as the US FDA approved Shield™ for colorectal cancer screening and early detection, as well as Guardant Reveal™ for minimal residual disease detection and recurrence monitoring and Guardant360® and Guardant360 TissueNext™ for comprehensive genomic profiling across all solid cancers.
The introduction of the Shield™ test for colorectal cancer screening marks a transformative step in advancing precision and preventive healthcare across the region.
About Hikma
For more than 45 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across North America, MENA and Europe. For more information, please visit: www.hikma.com
*Source: AETOSWire
Contacts:
Enquiries:
Bedour Mossa
Senior PR Account Manager
APCO
bmossa@apcoworldwide.com
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Campaign ME
17-07-2025
- Campaign ME
Edelman UAE makes key leadership appointments
Edelman has announced new leadership appointments across its UAE team in an effort to reinforce its specialist capabilities in Health, Crisis & Risk, and Brand. These internal moves promotions aim to reflect Edelman's ongoing investment in integrated, sector-led communications and the strength of its senior talent across the region. Lauren Brush has assumed the role of Head of Health, bringing a track record of advising high-profile global stakeholders, including the Saudi Ministry of Health and leading U.S.-based medical associations. Her work spans pandemic response, BRCA testing, and the launch of the UAE's first-ever telemedicine portal. Already a key advisor on Edelman's partnership with M42 and its expansive portfolio, Brush will now lead the development of the firm's health offer in the region, helping clients navigate an increasingly high-impact and rapidly shifting sector. Chase Burns has been appointed Head of Crisis & Risk, expanding his role within Edelman's Corporate Practice. He currently leads the work for the Abu Dhabi Investment Office (ADIO), Hub71 and ATRC. With more than 15 years of experience both in-house and advising clients through high-stakes, reputationally sensitive situations across aviation, advanced technology and sovereign investment, Burns has overseen responses to aircraft groundings, geopolitical attacks, and pandemic-related disruptions. As scrutiny intensifies and exposure to misinformation and disinformation, operational disruption, and geopolitical risks grows, Burns will lead the development of Edelman's integrated crisis and risk advisory services in the region, helping clients anticipate, navigate and recover from complex situations, while also representing the region within Edelman's global crisis leadership team. Lastly, Deepanshi Tandon has been appointed Head of Brand for Edelman UAE. In her role, she will lead the Brand practice, building on Edelman's expertise in creating earned-first, trusted brands that drive influence and shape culture. She brings more than 15 years of experience and has led several global brands across markets and sectors, spearheading strategic, creative, and culturally resonant work. Tandon currently leads work for clients such as PepsiCo and Nissan Middle East and has played a central role in shaping brand reputation strategies and leading integrated, multi-channel campaigns that drive cultural relevance and impact. On the appointments, Omar Qirem, CEO, Edelman Middle East, said: 'These leadership updates reflect both our investment in specialist talent and our commitment to developing leadership from within. Lauren, Chase and Deepanshi bring a powerful combination of subject matter expertise, client trust, and integrated thinking that will be instrumental to our next chapter of growth in the region.' The global communications firm operates wholly owned offices in Abu Dhabi, Dubai, and Riyadh as part of Edelman's broader Middle East network.
Zawya
17-07-2025
- Zawya
Hikma, IFC sign $250mln deal for MENA medicine access
Hikma Pharmaceuticals (Hikma), a multinational pharmaceutical company, and the International Finance Corporation (IFC), a member of the World Bank Group, have signed a $250 million six-year financing agreement focused on expanding access to medicines to support Hikma's operations across the Middle East and North Africa region (MENA), by strengthening local medicine production. This financing builds on IFC's anchor role in Hikma's $500 million, five-year bond issuance, which included a $50 million subscription from IFC. The latest investments mark another milestone in a 40-year partnership and reaffirm IFC's commitment to supporting Hikma's mission of providing high-quality, affordable medicines across key MENA markets. 'Our longstanding partnership with IFC has supported our expansion into new markets over the past four decades, most recently through the strategic $250 million loan and contribution to our $500 million bond issuance. This has allowed us to respond effectively to critical healthcare needs in the regional markets we serve.' said Mazen Darwazah, Hikma's Executive Vice Chairman and President of MENA. 'Our partnership transcends monetary transactions and reflects our long-term alignment and shared values on corporate governance and sustainability. Together, we have grown strategically while staying focused on what matters most; supporting our patients by addressing high unmet healthcare needs across the region.' Khawaja Aftab Ahmed, IFC's Regional Director for the Middle East, Pakistan, and Afghanistan, added: 'IFC's 40-year partnership with Hikma continues to demonstrate what's possible when global development institutions and private sector leaders collaborate. Together, we've expanded access to high-quality medicines across emerging markets, enabling the company to grow into new territories and deliver critical medicine when it was needed most, including during the Covid-19 pandemic. Our recent engagements build on that strong foundation and open the door for even greater impact by supporting local medicine production and continued regional growth, despite ongoing conflict and uncertainty.' -TradeArabia News Service Copyright 2024 Al Hilal Publishing and Marketing Group Provided by SyndiGate Media Inc. (
Zawya
09-07-2025
- Zawya
M42, GE HealthCare join forces to advance AI-Enabled Patient Care
M42, a global health leader powered by technology, artificial intelligence and genomics, will collaborate with GE HealthCare, a global innovator in medical technology, pharmaceutical diagnostics and integrated, cloud-first AI-enabled digital solutions, to enhance diagnostic precision and deliver more personalised patient outcomes, marking a significant step forward in the future of smart healthcare in the UAE. M42 and GE HealthCare will harness their combined strengths in advanced AI-powered solutions and explore collaborative go-to-market initiatives to deliver smarter, more connected healthcare in the region, with a focus on improving both clinical and operational efficiency. Leveraging M42's advanced AI, data and technology platforms alongside GE HealthCare's deep expertise in medical technology and product development, this collaboration will focus on co-developing innovative solutions to tackle pain points in healthcare systems and help support business and operational outcomes. By integrating AI with multimodal data analysis, M42 and GE HealthCare aim to accelerate product development and further position the region as a growing hub for life sciences innovation. Dimitris Moulavasilis, Group Chief Executive Officer at M42, said, 'Our collaboration with GE HealthCare is another step forward in M42's journey to disrupt traditional healthcare systems and positively impact people. By combining our strengths, we will be developing and deploying tech-enabled solutions to tackle the toughest challenges in the healthcare sector, delivering real, measurable outcomes for both patients and health systems. Together, we aren't just reimagining the future of precision medicine and smart care; we're building it here in the UAE and scaling it to the world.' Konstantinos Deligiannis, EAGM (Eurasian and African Growth Markets), President of GE HealthCare, added, 'We are committed to driving precision care through innovation and collaboration. Our collaboration with M42 represents a powerful convergence of advanced AI, data, and clinical expertise, and is a testament to our shared vision of delivering smarter, more connected healthcare solutions that improve outcomes for patients everywhere.' Leveraging the UAE's innovation-friendly ecosystem, this partnership reflects the country's ambition to lead in global health innovation by advancing world-class, patient-centered care. In partnering with a global health tech giant, M42 continues to progress smarter, more personalised care for communities in the UAE and beyond. M42's Diaverum business has taken 30 years of dialysis know-how to develop an AI-powered digital platform that not only reduces hospital stays, but has decreased the mortality rate, predicting thrombotic events before they occur. M42 has also developed and deployed Med42 LLM model, a large language model designed for clinical use cases and available for research use as an open-source solution. The company's AIRIS-TB conducts 2,000 AI-powered chest X-ray examinations daily to screen for tuberculosis against 200 conducted via conventional methods.
